拨康视云-B(02592)今日在港交所主板挂牌上市,盘中大跌7.43%,股价跌至9.35港元,较10.1港元的招股价下跌超过13%,引发市场关注。
拨康视云-B是一家临床阶段眼科生物科技公司,致力于开发新型及差异化疗法。公司此次通过全球发售约6058.2万股股份,募集资金净额约5.22亿港元。值得注意的是,公司香港公开发售部分获得78.78倍超额认购,显示出投资者的初步热情。
然而,该股今日开盘即表现疲软,开盘价为9.5港元,较招股价低5.94%。随后股价继续下滑,盘中最多下跌7.43%。分析人士指出,尽管公司IPO获得较高认购倍数,但上市首日股价表现不佳,可能反映了投资者对生物科技公司长期盈利能力的担忧,以及当前市场对新股的谨慎态度。此外,全球经济不确定性和生物科技行业的激烈竞争也可能影响了投资者信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.